Naturally occurring CD7‐T and genetically modified CD7‐targeting allogeneic CAR‐T cells both displayed an ideal therapeutic effect on hematological malignancies especially acute T‐cell lymphcarcinoma [37, 38, 39]. This evidence concerns the gene CD7 and hematologic disorder.